
https://www.science.org/content/blog-post/speed-meldonium
# Up to Speed on Meldonium (March 2016)

## 1. SUMMARY  
The 2016 commentary introduced meldonium (also called mildronate), a Latvian‑origin drug approved only in parts of the former Soviet Union for treating cardiac ischemia. The author explained that the compound inhibits carnitine biosynthesis, which can improve blood‑flow and reduce metabolic stress. Because of these effects, meldonium attracted attention when Russian tennis star Maria Sharapova tested positive for it after the World Anti‑Doping Agency (WADA) added the substance to its prohibited list earlier that year. The piece questioned Sharapova’s medical justification (magnesium deficiency and family history of diabetes) and suggested that the drug’s limited commercial appeal outside the ex‑Soviet bloc stemmed from weak patent prospects and a lack of Western regulatory approval.

## 2. HISTORY  
**Regulatory status** – Since the 2016 ban, meldonium has remained on WADA’s “S4 – Hormone and Metabolic Modulators” list (as of the 2024 Prohibited List). It has **never obtained FDA or EMA approval**, and no Western‑marketed formulation has been launched.

**Clinical development** – Post‑2016, most clinical trials continued to be conducted in Russia, Belarus, and a few Eastern‑European centers. Small‑scale studies explored its use in chronic heart failure, post‑myocardial‑infarction remodeling, and peripheral arterial disease. None have progressed to pivotal Phase III trials, and no new indications have been approved by any major health authority.

**Commercial impact** – The Latvian company Grindeks (the original manufacturer) continued to sell meldonium domestically and in a handful of CIS countries, generating modest revenues (estimated under €10 million annually). There has been **no significant expansion** into Western markets, and no major biotech or pharma partnership has been announced.

**Athletics** – After Sharapova’s 15‑month suspension (originally two years, reduced on appeal), she returned to competition in April 2017. Several other athletes—mainly from Eastern Europe—tested positive for meldonium in 2016‑2018, but the number of violations dropped sharply after the ban’s first year, likely because athletes discontinued use. No high‑profile cases have emerged since 2020.

**Scientific perception** – The mechanistic rationale (inhibition of γ‑butyrobetaine hydroxylase, reducing carnitine synthesis) remains accepted, but meta‑analyses of the limited human data conclude that **evidence for performance enhancement is weak** and that any cardioprotective benefit is modest and not superior to established therapies (e.g., beta‑blockers, ACE inhibitors). Consequently, meldonium is **not widely adopted** in research labs outside the former Soviet sphere.

**Policy** – The episode reinforced WADA’s willingness to ban substances with limited clinical data but plausible metabolic effects. It also prompted the agency to tighten its monitoring of “novel” Eastern‑European drugs, but no broader policy shift directly attributable to meldonium occurred.

## 3. PREDICTIONS  
The article did not contain explicit forecasts, but it implied several expectations:

- **Prediction:** Meldonium would remain a niche drug, unlikely to achieve Western regulatory approval.  
  **Outcome:** Correct. As of 2025, it is still unapproved in the US, EU, and Japan.

- **Prediction:** The substance would stay prohibited for athletes, with limited future doping cases.  
  **Outcome:** Accurate. It remains on the WADA prohibited list, and the bulk of positive tests occurred in the first two years after the ban.

- **Prediction (implicit):** Sharapova’s medical justification would be dubious and the ban would damage her endorsements.  
  **Outcome:** Sharapova’s claim was widely viewed as insufficient; she lost several sponsorships and served a 15‑month suspension before returning to the tour.

- **Prediction (implicit):** No major commercial or scientific breakthrough would emerge from meldonium.  
  **Outcome:** So far, no large‑scale clinical trials, no FDA/EMA approval, and no blockbuster sales have materialized.

## 4. INTEREST  
**Rating: 6/10** – The article is moderately interesting because it captures a rare intersection of Cold‑War‑era pharmacology, elite sport, and anti‑doping policy, but the drug itself has not generated lasting scientific or commercial impact.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20160308-speed-meldonium.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_